Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-6250 in healthy volunteers
NCT06740474Phase 1Completed
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Jan 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABI-6250 in Hepatitis delta virus infection (HDV) (6 arms), sponsored by Assembly Biosciences, Inc. Primary endpoints: Adverse Events, Area Under the Plasma Concentration Time Curve and 6 more. Started Jan 2025; status: completed.
02
Drugs
ABI-6250
03
Conditions
Hepatitis delta virus infection (HDV)
Beyond the preview
Go deeper on NCT06740474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06740474.